Abstract 1829P
Background
To investigate the nutritional status of hospitalized patients with common malignant tumor in a cancer hospital of Southwest China.
Methods
From April 2017 to May 2021, we enrolled 891 patients with cancer hospitalized for treatment in Chongqing university Cancer Hospital. These patients were diagnosed with one of the following 16 different types of malignant tumors: lung cancer, gastric cancer, liver cancer, colorectal cancer, breast cancer, esophageal cancer, cervical cancer, endometrial cancer, nasopharyngeal carcinoma, malignant lymphoma, leukemia, pancreatic cancer, ovarian cancer, prostate cancer, bladder cancer and brain tumor. Patient-generated subjective global assessment (PG-SGA), anthropometric measurements, and laboratory examination were used to evaluate the nutritional risk or nutritional status.Cancer pain status were assessed with the Numerical Rating Scale (NRS). We also investigated the nutritional therapy of these cancer patients.
Results
According to the PG-SGA score, 48.7% (434/891) of the cancer patients were severe malnutrition (PG-SGA≥9), 31.2% (312/891) were moderate malnutrition (8≥PG-SGA≥4), 14.7% (131/891) were mild malnutrition (PG-SGA 2∼3), and only 5.4% (48/891) patients were no malnutrition (PG-SGA 0∼1). The rate of malnutrition for gastrointestinal cancer patients is higher than Nongastrointestinal cancer patients (67.3% vs. 44.6%, χ2=31.48, P <0.001). Multiple linear regression analysis, PG-SGA scores and body mass index (P<0.001), serum total protein(P<0.001), hemoglobin serum(P<0.001), albumin (P<0.001), prealbumin (P<0.001), calf circumference (left side, P=0.001) were correlated. Age(≥65 years), albumin(<40g/L), prealbumin (<150mg/L) and cancer pain (NRS≥4) are the risk factors of severe malnutrition. However, only 26.8% (200/746) of all the moderately and severely malnourished patients received nutritional therapy.
Conclusions
94.6% of the common malignant tumor patients enrolled in the present study were malnutrition. Nutritional therapy of malignant tumor patients with malnutrition is very low.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1906P - ESMO-ESTRO consensus recommendations regarding the safety of combining radiotherapy with targeted agents or immunotherapy
Presenter: Evert van Aken
Session: Poster session 12
1907P - Deployment of remote patient monitoring in older patients: A real-world experience from 2419 patients across 58 centres in France and Belgium
Presenter: Nicolas Bertrand
Session: Poster session 12
1908P - Grading the evidence for physical activity and all outcomes in cancer survivors: An umbrella review of more than 700 meta-analytic associations
Presenter: Panagiotis Filis
Session: Poster session 12
1909TiP - Home-based physical exercise during neoadjuvant treatment for early breast cancer patients (HoPEx-Breast): A pragmatic randomised controlled trial
Presenter: Rita Pichel
Session: Poster session 12
1943P - Updated pan-tumor guidelines for neoadjuvant scoring of pathologic response: A joint SITC and INMC effort
Presenter: Julie Deutsch
Session: Poster session 12
1944P - Super-enhancer driven NR3C1 expression promotes 5-FU resistance in gastric cancer
Presenter: Bingya Liu
Session: Poster session 12
Resources:
Abstract
1945P - Stroma-derived bIgH3 (βigH3/TGFBI) is the local mediator of pathological TGFβ activity in pancreatic cancer and a target to treat in patients with high fibrotic activity
Presenter: Morten Karsdal
Session: Poster session 12
1946P - SLC7A9 suppression increases chemosensitivity by inducing ferroptosis via inhibiting cystine transportation in gastric cancer
Presenter: Jianfang Li
Session: Poster session 12
Resources:
Abstract
1947P - Organoid establishment from multiple biological sources in biliopancreatic cancers
Presenter: Michele Zanoni
Session: Poster session 12
1948P - Analysis of cytokines, chemokines, and tumor-infiltrating lymphocytes as immunological markers predicting pathological complete response in triple-negative breast cancer: Exploratory analysis of the NACATRINE trial
Presenter: Ana Julia de Freitas
Session: Poster session 12